

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

May 2011

Vol. 39, No. 5

CONTENTS

SHORT COMMUNICATIONS

Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics. *Birk Poller, Dilek Iusuf, Rolf W. Sparidans, Els Wagenaar, Jos H. Beijnen, and Alfred H. Schinkel* **729**

In Vivo Magnetic Resonance Imaging to Detect Biliary Excretion of ¹⁹F-Labeled Drug in Mice. *Jean-Pierre Raufman, Su Xu, Kunrong Cheng, Sandeep Khurana, Diana Johnson, Changxing Shao, Maureen A. Kane, Da Shi, Rao Gullapalli, and James Polli* **736**

ARTICLES

Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite. *Anthony G. Borel, Timothy M. Jones, Robert J. Barbuch, David A. Jackson, Palaniappan Kulanthaivel, Edward Mattiuz, Valentine J. Klimkowski, William J. Wheeler, and Gregory A. Renner* **740**

Identification of the Metabolites of the Antioxidant Flavonoid 7-Mono-O-(β -hydroxyethyl)-rutoside in Mice. *Hilde Jacobs, Ron Peters, Gertjan J. M. den Hartog, Wim J. F. van der Vijgh, Aalt Bast, and Guido R. M. M. Haenen* **750**

Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CYP3A5-Mediated Midazolam 1'-Hydroxylation. *Minako Sugiyama, Ken-ichi Fujita, Norie Murayama, Yuko Akiyama, Hiroshi Yamazaki, and Yasutsuna Sasaki* **757**

Novel Cytochrome P450-Mediated Ring Opening of the 1,3,4-Oxadiazole in Setileuton, a 5-Lipoxygenase

Inhibitor. *Cheri M. Maciolek, Bennett Ma, Karsten Menzel, Sebastien Laliberte, Kevin Bateman, Paul Krolkowski, and Christopher R. Gibson* **763**

Influence of Drug Solubility and Lipophilicity on Transscleral Retinal Delivery of Six Corticosteroids. *Ashish Thakur, Rajendra S. Kadam, and Uday B. Kompella* **771**

Anandamide Oxidation by Wild-Type and Polymorphically Expressed CYP2B6 and CYP2D6. *Chitra Sridar, Natasha T. Snider, and Paul F. Hollenberg* **782**

Pharmacokinetic Interaction of the Antiparasitic Agents Ivermectin and Spinosad in Dogs. *Stewart T. Dunn, Laura Hedges, Kathleen E. Sampson, Yurong Lai, Sean Mahabir, Larissa Balogh, and Charles W. Locuson* **789**

Contribution of Carboxylesterase in Hamster to the Intestinal First-Pass Loss and Low Bioavailability of Ethyl Piperate, an Effective Lipid-Lowering Drug Candidate. *Youli Lu, Narisu Bao, Gereltu Borjihan, Yanling Ma, Miaomiao Hu, Chen Yu, Shuijun Li, Jingying Jia, Ding Yang, and Yiping Wang* **796**

Metabolism of the c-Fos/Activator Protein-1 Inhibitor T-5224 by Multiple Human UDP-Glucuronosyltransferase Isoforms. *Shinsuke Uchihashi, Hiroyuki Fukumoto, Makoto Onoda, Hiroyoshi Hayakawa, Shin-ichi Ikushiro, and Toshiyuki Sakaki* **803**

Organic Anion Transporter 3 Mediates the Efflux Transport of an Amphipathic Organic Anion, Dehydroepiandrosterone Sulfate, across the Blood-Brain Barrier in Mice. *Mari Miyajima, Hiroyuki*

Continued on next page

Drug Metabolism and Disposition (ISSN 0090-9556) is published monthly (one volume per year) by the American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995; e-mail: subscriptions@aspet.org; Web site: aspet.org. Periodicals postage paid at Bethesda, MD, and at additional mailing offices. POSTMASTER: Send address changes to *Drug Metabolism and Disposition*, 9650 Rockville Pike, Bethesda, MD 20814-3995. Subscription rates: U.S.: \$453; outside the U.S.: \$532. Single copy: \$40. GST Tax Number for Canadian subscribers: BN:13489 2330 RT. Indexed or abstracted by *Biochemistry & Biophysics Citation Index*®, *Biological Abstracts*, *BIOSIS Previews Database*, *BioSciences Information Services*, *Current Awareness in Biological Sciences*, *Current Contents/Life Sciences*, *EMBASE/Excerpta Medica*, *Index Medicus*, *International Pharmaceutical Abstracts*, *Medical Documentation Service*®, *Reference Update*®, *Research Alerts*®, *Science Citation Index*®, *SciSearch*®, and *SIIC Data Bases* Copyright © 2011 by the American Society for Pharmacology and Experimental Therapeutics. All rights reserved. Printed in the U.S.A.

Downloaded from dmd.aspetjournals.org at ASPET Journals on February 19, 2018

DRUG METABOLISM & DISPOSITION

<i>Kusuhara, Miki Fujishima, Yasuhisa Adachi, and Yuichi Sugiyama</i>	814	Enzymes. <i>Romi Ghose, Tao Guo, Jesus G. Vallejo, and Adarsh Gandhi</i>	874
Human Pharmacokinetic Prediction of UDP-Glucuronosyltransferase Substrates with an Animal Scale-Up Approach. <i>Tsuneo Deguchi, Nobuaki Watanabe, Atsushi Kurihara, Katsuhiko Igeta, Hidenori Ikenaga, Keiichi Fusegawa, Norio Suzuki, Shinji Murata, Masakazu Hirouchi, Yoshitake Furuta, Masaru Iwasaki, Osamu Okazaki, and Takashi Izumi</i>	820	Liver-Selective Expression of Human Arylamine <i>N</i> -Acetyltransferase NAT2 in Transgenic Mice. <i>Kim S. Sugamori, Debbie Brenneman, and Denis M. Grant</i>	882
☐ Evaluation of the Effects of 20 Nonsynonymous Single Nucleotide Polymorphisms of CYP2C19 on <i>S</i> -Mephenytoin 4'-Hydroxylation and Omeprazole 5'-Hydroxylation. <i>Huijuan Wang, Nianzhen An, Hao Wang, Yiwen Gao, Duan Liu, Ting Bian, Juanli Zhu, and Chao Chen</i>	830	☐ Metabolism and Disposition of [¹⁴ C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans. <i>Jiachang Gong, Jinping Gan, Janet Caceres-Cortes, Lisa J. Christopher, Vinod Arora, Eric Masson, Daphne Williams, Janice Pursley, Alban Allentoff, Michael Lago, Scott B. Tran, and Ramaswamy A. Iyer</i>	891
☐ CYP2C9-Mediated Metabolic Activation of Losartan Detected by a Highly Sensitive Cell-Based Screening Assay. <i>Atsushi Iwamura, Tatsuki Fukami, Hiroko Hosomi, Miki Nakajima, and Tsuyoshi Yokoi</i>	838	Reevaluation of the Microsomal Metabolism of Montelukast: Major Contribution by CYP2C8 at Clinically Relevant Concentrations. <i>Anne M. Filpula, Jouko Laitila, Pertti J. Neuvonen, and Janne T. Backman</i>	904
☐ In Vivo Investigation in Pigs of Intestinal Absorption, Hepatobiliary Disposition, and Metabolism of the 5 α -Reductase Inhibitor Finasteride and the Effects of Coadministered Ketoconazole. <i>Anna Lundahl, Mikael Hedeland, Ulf Bondesson, and Hans Lennernäs</i>	847	The Development of UDP-Glucuronosyltransferases 1A1 and 1A6 in the Pediatric Liver. <i>Shogo J. Miyagi and Abby C. Collier</i>	912
☐ Optimal Experimental Design for Assessment of Enzyme Kinetics in a Drug Discovery Screening Environment. <i>Erik Sjögren, Joakim Nyberg, Mats O. Magnusson, Hans Lennernäs, Andrew Hooker, and Ulf Bredberg</i>	858	Interactions of Green Tea Catechins with Organic Anion-Transporting Polypeptides. <i>Megan Roth, Barbara N. Timmermann, and Bruno Hagenbuch</i>	920
☐ Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data. <i>Helen E. Cubitt, J. Brian Houston, and Aleksandra Galletin</i>	864	Effect of the <i>CYP2C8</i> Genotype on the Pharmacokinetics and Pharmacodynamics of Repaglinide. <i>Dorota Tomalik-Scharte, Uwe Fuhr, Martin Hellmich, Dorothee Frank, Oxana Doroshyenko, Alexander Jetter, and Julia C. Stingl</i>	927
☐ Differential Role of Toll-Interleukin 1 Receptor Domain-Containing Adaptor Protein in Toll-Like Receptor 2-Mediated Regulation of Gene Expression of Hepatic Cytokines and Drug-Metabolizing			

ACCELERATED COMMUNICATION

Seasonal Variation in Blood Drug Concentrations and a Potential Relationship to Vitamin D. <i>Jonatan D. Lindh, Marine L. Andersson, Erik Eliasson, and Linda Björkhem-Bergman</i>	933
--	------------

ERRATUM

Correction to Table of Contents, Volume 39, Number 3, March 2011	938
--	------------

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Proposed metabolism of LY654322 to form M25. See the article by Borel et al. on page 740 of this issue.